Last updated: 07/17/2024 17:07:17
Exploratory Study of Biotelemetry in Amyotrophic Lateral Sclerosis
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: An Exploratory Study to Investigate the Use of Biotelemetry to Identify Markers of Disease Progression in Subjects with Amyotrophic Lateral Sclerosis
Trial description: Study 201283 is an exploratory, non-controlled, non-drug study in Amyotrophic Lateral Sclerosis (ALS) subjects. This study is being conducted as the first step for developing new meaningful measure(s) which might prove to be more effective than existing measures for monitoring clinical function and disease course in ALS. The objective of this study is to test novel measures of movement/physical activity, heart rate and speech and explore how they measure disease progression by evaluating their relationship to gold standard measures of function. This study will be conducted in two phases. A variable length Pilot Phase to test biotelemetry instruments and algorithms reliability and ease of use/acceptance. Approximately 5 subjects will have at least 1 clinic visit to perform a series of set reference tasks while wearing the accelerometer and electrode. Subjects will also continuously wear the accelerometer and electrode in their routine home-life setting for approximately 3 days after the clinic visit (i.e., home monitoring). Subjects in the Pilot Phase will continue in the study and participate in the Core Study Phase. A 48 week Core Study Phase will be conducted to evaluate how measures of movement/physical activity, speech and Heart Rate Variability (HRV) relate to ALS disease progression. During this phase, a maximum of 25 subjects will be enrolled. Subjects will attend 5 clinic visits to perform gold standard measures of function and perform a series of set reference tasks while wearing the accelerometer and electrode. In between clinic visits, every month subjects will attach the accelerometer and electrode and wear it for approximately 3 days in their home. A telephone contact with the subject will be made by the site at the end of each 3-day home monitoring period.All third party trademark rights are the rights of their respective owners.
Primary purpose:
Other
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
Not applicable
Primary outcomes:
Duration of day time wear time of the device
Timeframe: Up to Week 48
Secondary outcomes:
Not applicable
Interventions:
Device: Faros Sensor (FS) and LifeInsight Hub
Device: Fast Fix electrode patch
Procedure/surgery: Quantitative Measure of Speech (Core Phase Only)
Enrollment:
25
Observational study model:
Not applicable
Primary completion date:
2017-01-06
Time perspective:
Not applicable
Clinical publications:
Kelly ML, Lavrov A, Garcia-Gancedo L, Parr J, Hart R, Chiwera T, Shaw CE, Al Chalabi A, Marsden R, Turner MR, Talbot K. The Use of Biotelemetry to Explore Disease Progression Markers in Amyotrophic Lateral Sclerosis. Amyotroph Lateral Scler. 2020
DOI: 10.1080/21678421.2020.1773501
Pub Med ID: 32573278
Garcia-Gancedo L, Kelly ML, Lavrov A, Parr J, Hart R, Marsden R, Turner M, Talbot K, Chiwera T, Shaw CE, Al Chalabi A.Objectively Monitoring Amyotrophic Lateral Sclerosis Patient Symptoms During Clinical Trials With Sensors: Observational Study.JMIR Mhealth Uhealth.2019;7(12):e13433
DOI: 10.2196/13433
PMID: 31859676
Medical condition
Amyotrophic Lateral Sclerosis
Product
Not applicable
Collaborators
Not applicable
Study date(s)
June 2015 to June 2017
Type
Interventional
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
18 - 80 years
Accepts healthy volunteers
No
- Between 18 and 80 years of age, inclusive, at the time of signing the informed consent.
- Diagnosed with ALS by a neurologist with expertise in ALS. For subjects with bulbar onset there must be objective limb involvement of at least one limb.
- Neurological (other than the subject’s ALS) or non-neurological co-morbidities (e.g. joint disease, respiratory disease) which limit mobility.
- Clinically significant cognitive impairment in the opinion of the investigator.
Inclusion and exclusion criteria
Inclusion criteria:
- Between 18 and 80 years of age, inclusive, at the time of signing the informed consent.
- Diagnosed with ALS by a neurologist with expertise in ALS. For subjects with bulbar onset there must be objective limb involvement of at least one limb.
- Diagnosed with ALS within 18 months of symptom onset.
- Subjects must be ambulatory (i.e., must not be confined to a wheelchair).
- Male and female subjects.
- Capable of giving signed (or verbal consent or assent where applicable) informed consent as described in Protocol which includes compliance with the requirements and restrictions listed in the consent form and in protocol.
- Capable and willing to comply with the requirements of the protocol (either by themselves or with assistance).
Exclusion criteria:
- Neurological (other than the subject’s ALS) or non-neurological co-morbidities (e.g. joint disease, respiratory disease) which limit mobility.
- Clinically significant cognitive impairment in the opinion of the investigator.
- Regionally restricted forms of ALS, or other atypical variants: Isolated corticobulbar pattern of ALS with normal ambulation; Flail arm syndrome; Primary lateral sclerosis; Signs of chronic partial denervation restricted to a single limb; ALS parkinsonism dementia complex
- Subjects requiring mechanical ventilation (non-invasive ventilation for sleep apnoea is allowed).
- Historical or current evidence of clinically significant uncontrolled disease which, in the opinion of the investigator, would put the safety of the subject at risk through participation or impact the study assessments or endpoints.
- Presence of an active implantable cardiac medical device (e.g., pacemaker or implantable cardioverter-defibrillator) or at a high risk for needing external defibrillation.
- History of skin hypersensitivity to adhesives.
- Current participation in a clinical trial which in the opinion of the investigator and GSK medical monitor might impact the objectives of this study.
Trial location(s)
Study documents
Protocol
Available language(s): English
Statistical analysis plan
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Recruitment status
Completed
Actual primary completion date
2017-01-06
Actual study completion date
2017-01-06
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website